Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_assertion type Assertion NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_head.
- NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_assertion description "[The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_provenance.
- NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_assertion evidence source_evidence_literature NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_provenance.
- NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_assertion SIO_000772 14750179 NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_provenance.
- NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_assertion wasDerivedFrom befree-20150227 NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_provenance.
- NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_assertion wasGeneratedBy ECO_0000203 NP722769.RA6Uz-k8F7rW_vQ935CauyBSnmJQ3Bn7fA1rpRX6o2nGA130_provenance.